MarketCap
Protagonist Therapeutics PTGX
$ 136.18
0.21%
Facebook
X
Telegram
Protagonist Therapeutics EV/EBITDA Ratio | PTGX
Annual EV/EBITDA Ratio Protagonist Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.8 | 9.36 | -16.4 | -8.36 | -10.2 | -10.1 | -2.14 | -2.36 | -7.54 | -3.13 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.36 | -34.8 | -8.56 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
52.9 | - | - | $ 5.18 B |  USA |
 |
Athira Pharma
ATHA
|
0.0485 | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
2.95 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
3.06 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.13 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-1.22 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
0.177 | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
-0.864 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
0.36 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
-2.07 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
0.709 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
0.257 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
0.257 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
0.127 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-11 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-2.01 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
19.2 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
26.3 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-0.0912 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-1.49 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-1.65 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
121 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-0.342 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
1.13 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
1.15 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-0.378 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
2.25 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
0.512 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
6.05 | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
0.252 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-0.517 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
0.69 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-8.5 | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-1.15 | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
0.343 | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-4.63 | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
0.0763 | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-75.8 | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
0.328 | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-0.933 | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-0.417 | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-1.34 | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
-2.28 | $ 8.74 | 0.52 % | $ 606 M | USA |
|
BiomX
PHGE
|
-0.109 | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
0.684 | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-2.06 | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
0.144 | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
1.46 | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-2.89 | - | -6.08 % | $ 184 M | China |
 |
Cassava Sciences
SAVA
|
-0.543 | - | - | $ 110 M | USA |